Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2014 | Pages:
40 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Catalyst Pharmaceutical Partners, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Catalyst Pharmaceutical Partners, Inc. - Product Pipeline Review - 2014', provides an overview of the Catalyst Pharmaceutical Partners, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Catalyst Pharmaceutical Partners, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Catalyst Pharmaceutical Partners, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Catalyst Pharmaceutical Partners, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Catalyst Pharmaceutical Partners, Inc.'s pipeline products Reasons to buy - Evaluate Catalyst Pharmaceutical Partners, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Catalyst Pharmaceutical Partners, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Catalyst Pharmaceutical Partners, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Catalyst Pharmaceutical Partners, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Catalyst Pharmaceutical Partners, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Catalyst Pharmaceutical Partners, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Catalyst Pharmaceutical Partners, Inc. Snapshot 4 Catalyst Pharmaceutical Partners, Inc. Overview 4 Key Information 4 Key Facts 4 Catalyst Pharmaceutical Partners, Inc. - Research and Development Overview 5 Key Therapeutic Areas 5 Catalyst Pharmaceutical Partners, Inc. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Pipeline Products - Partnered Products 9 Partnered Products/Combination Treatment Modalities 10 Catalyst Pharmaceutical Partners, Inc. - Pipeline Products Glance 11 Catalyst Pharmaceutical Partners, Inc. - Late Stage Pipeline Products 11 Phase III Products/Combination Treatment Modalities 11 Catalyst Pharmaceutical Partners, Inc. - Clinical Stage Pipeline Products 12 Phase I Products/Combination Treatment Modalities 12 Catalyst Pharmaceutical Partners, Inc. - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Catalyst Pharmaceutical Partners, Inc. - Unknown Stage Pipeline Products 14 Unknown Products/Combination Treatment Modalities 14 Catalyst Pharmaceutical Partners, Inc. - Drug Profiles 15 amifampridine 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 vigabatrin 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 CPP-115 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Catalyst Pharmaceutical Partners, Inc. - Pipeline Analysis 21 Catalyst Pharmaceutical Partners, Inc. - Pipeline Products by Target 21 Catalyst Pharmaceutical Partners, Inc. - Pipeline Products by Route of Administration 22 Catalyst Pharmaceutical Partners, Inc. - Pipeline Products by Molecule Type 23 Catalyst Pharmaceutical Partners, Inc. - Pipeline Products by Mechanism of Action 24 Catalyst Pharmaceutical Partners, Inc. - Recent Pipeline Updates 25 Catalyst Pharmaceutical Partners, Inc. - Discontinued Pipeline Products 33 Discontinued Pipeline Product Profiles 33 vigabatrin 33 Catalyst Pharmaceutical Partners, Inc. - Company Statement 34 Catalyst Pharmaceutical Partners, Inc. - Locations And Subsidiaries 38 Head Office 38 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 40 Disclaimer 40
List of Tables Catalyst Pharmaceutical Partners, Inc., Key Information 4 Catalyst Pharmaceutical Partners, Inc., Key Facts 4 Catalyst Pharmaceutical Partners, Inc. - Pipeline by Indication, 2014 6 Catalyst Pharmaceutical Partners, Inc. - Pipeline by Stage of Development, 2014 7 Catalyst Pharmaceutical Partners, Inc. - Monotherapy Products in Pipeline, 2014 8 Catalyst Pharmaceutical Partners, Inc. - Partnered Products in Pipeline, 2014 9 Catalyst Pharmaceutical Partners, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 10 Catalyst Pharmaceutical Partners, Inc. - Phase III, 2014 11 Catalyst Pharmaceutical Partners, Inc. - Phase I, 2014 12 Catalyst Pharmaceutical Partners, Inc. - Preclinical, 2014 13 Catalyst Pharmaceutical Partners, Inc. - Unknown, 2014 14 Catalyst Pharmaceutical Partners, Inc. - Pipeline by Target, 2014 21 Catalyst Pharmaceutical Partners, Inc. - Pipeline by Route of Administration, 2014 22 Catalyst Pharmaceutical Partners, Inc. - Pipeline by Molecule Type, 2014 23 Catalyst Pharmaceutical Partners, Inc. - Pipeline Products by Mechanism of Action, 2014 24 Catalyst Pharmaceutical Partners, Inc. - Recent Pipeline Updates, 2014 25 Catalyst Pharmaceutical Partners, Inc. - Discontinued Pipeline Products, 2014 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
